Upbeat Drug Delivery Stocks - Delcath Systems (DCTH), Elan Corporation (ELN), Hospira (HSP)

New York, NY -- (SBWIRE) -- 03/12/2013 -- StockRunway.com issues special report on the Upbeat Drug Delivery Stocks – Delcath Systems, Inc (NASDAQ:DCTH), Elan Corporation, plc (ADR) (NYSE:ELN), Hospira, Inc (NYSE:HSP)

Delcath Systems, Inc (NASDAQ:DCTH) moved up +8.67% with the closing price of $2.13. The company, which is expected to report results on Wednesday, is said to be trying to cash in on its drug/device combination product, the Delcath Hepatic Delivery System, for uses in oncology. It is primarily keeping its focus on treating major and metastatic liver cancers.

The company is still early in its revenue-generating cycle and Wall Street expects it to have just $6.6 million in revenue this year, but that's a key improvement from 2012 where it likely generated less than $0.5 million. The overall volume in the last trading session was 6.71 million shares. Its fifty two week range was $1.01-$4.01. The total market capitalization remained $159.91million.

For How Long DCTH will Fight for Profitability? Read This Trend Analysis report

The stock is ahead its 52 week low with 110.89% and its last month price volatility remained 5.94%. Its beta coefficient was 1.86 with a target price of $4.76. In its share capital, the company has 76.82 million outstanding shares while 67.66 million shares have been floated in market.

It has insider ownership of 2.26% with its institutional ownership remained 11.25%. Its current year earnings per share grew with 42.98%.

Elan Corporation, plc (ADR) (NYSE:ELN) shares went 3.66% up and closed at $11.88 in the last trading session after issuing an update on Tysabri deal and $1Billion stock buyback plan. The company disclosed that the regulatory closing conditions linked to the Tysabri Transaction are the review process under the Hart-Scott-Rodino Antitrust Improvements Act (HSR) in the United States and the review by the Spanish Competition Authority in Europe.

For How Long ELN’s Gloss will Attract Investors? Find out via this report

For the US antitrust review under HSR, the waiting period expires on March 8, 2013. Its overall traded volume was 7.18 million shares. The stock’s opening price was $11.84, hitting the day high price of $11.95 and day low of $11.75. ELN has earnings per share of -$0.63. The company has -21.96% returns on assets, -52.49% returns on equity and its return on investments is -27.03%.

Hospira, Inc (NYSE:HSP) surged +1.59% to close at $30.59 and its total volume in the last trading session was 1.41 million shares. The company recently voluntarily stopped all new sales of its intravenous infusion pumps while it clarifies problems in its quality management system. In last 52 weeks, high hit was $38.49 and low price in that period was $28.62.

The company has outstanding shares of 165.40million with the total market cap of $5.06 billion and its beta value stands at 0.83 times. It has current ratio of 2.68 and its debt-to-equity ratio is 0.57.

Will HSP Continue To Move Higher? Find Out Here

About StockRunway.com
StockRunway.com is an Elite Financial Stock website catering to individual investors, fund managers, investment bankers and equity analysts. Whether you're new to penny stocks or a seasoned veteran, you'll find all the information you will need right here! Our research is a remarkable educational tool for everyone to utilize.

Sign up TODAY and join the vast amount of investors already benefiting from the best free alerts from StockRunway's service today!

Disclaimer
This report/release/advertisement is a commercial advertisement and is for general information purposes only. Never invest in any stock featured on our site, Press Releases or emails unless you can afford to lose your entire investment. The disclaimer is to be read and fully understood before using our site, or joining our email list. PLEASE NOTE WELL: StockRunway.com and its employees are not a Registered Investment Advisor, Broker Dealer or a member of any association for other research providers in any jurisdiction whatsoever. Read our Full Disclaimer by visiting our website.

Read Our Full Disclaimer at: http://www.stockrunway.com/disclaimer/